Related references
Note: Only part of the references are listed.Marketed therapeutic antibodies compendium
Janice M. Reichert
MABS (2012)
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
Hans Ulrichts et al.
BLOOD (2011)
Shortened Engineered Human Antibody CH2 Domains INCREASED STABILITY AND BINDING TO THE HUMAN NEONATAL Fc RECEPTOR
Rui Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Stuart L. Emanuel et al.
MABS (2011)
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2010)
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Christian Zahnd et al.
CANCER RESEARCH (2010)
Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Engineered Human Antibody Constant Domains with Increased Stability
Rui Gong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Structural characterization of a human Fc fragment engineered for extended serum half-life
Vaheh Oganesyan et al.
MOLECULAR IMMUNOLOGY (2009)
Engineered CH2 domains (nanoantibodies)
Dimiter S. Dimitrov
MABS (2009)
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Volker Schellenberger et al.
NATURE BIOTECHNOLOGY (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics
C. Simone Fishburn
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers
Weizao Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease
Stefka B. Petkova et al.
INTERNATIONAL IMMUNOLOGY (2006)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Selection and characterization of HER2/neu-binding affibody ligands
M Wikman et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2004)
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gpl120 is sterically restricted on primary human immunodeficiency virus type 1
AF Labrijn et al.
JOURNAL OF VIROLOGY (2003)
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs
DC Roopenian et al.
JOURNAL OF IMMUNOLOGY (2003)
DX-88 and HAE: a developmental perspective
A Williams et al.
TRANSFUSION AND APHERESIS SCIENCE (2003)
PEGylated antibodies and antibody fragments for improved therapy: a review
AP Chapman
ADVANCED DRUG DELIVERY REVIEWS (2002)
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
RJ Ober et al.
INTERNATIONAL IMMUNOLOGY (2001)
Stability engineering of antibody single-chain Fv fragments
A Wörn et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Share Paper
